000			02956nam a22003495i 4500
001			81292
003			ES-MaUEC
005			20230207040322.0
007			cr nn 008mamaa
008			141203s2015 gw | s |||| 0|eng d
020			_a9783319121147
040			_aES-MaUEC
050		4	_aQP572.P74 _bR434 2015 EB
245	0	0	_aRecent Advances in Prolactin Research _cedited by Maria Diakonova, PhD.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (VIII, 281 p.) 54 il., 45 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v846
520			_aRecent Advances in Prolactin Research summarizes the current knowledge of prolactin (PRL), PRL receptor, PRL-dependent signaling pathways, the role of PRL in oncogenesis and PRL crosstalk with other oncogenic factors. The chapters are written by experts in these fields and focus on identifying and reviewing timely experimental findings that provide new insights into the expanding role of PRL in the pathophysiology associated with a variety of human conditions. Prolactin is a peptide hormone that is best known for its role in lactation. Prolactin also has an influence on hematopoiesis and angiogenesis, and is involved in the regulation of blood clotting through several pathways. Although PRL was discovered more than 80 years ago, the understanding of PRL signaling and its relationship to various pathologies is still very incomplete. PRL is not only a pituitary hormone with an important role in reproduction, but PRL also acts as a cytokine, modulating a wide variety of physiological processes. For example, data gathered during the last decade have demonstrated that locally produced PRL acts as the autocrine/paracrine factor and plays a contributory role during breast oncogenesis. In fact, the scientific and clinical communities have suggested that the manipulation of the PRL axis may lead to the successful treatment of breast cancer. However, recent work has demonstrated that the role of the PRL axis is much more complex than first envisaged.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		7	_aProlactina _9143208 _0comprobar BNE19901035357 _2embne
700	1		_aDiakonova, Maria _eeditor literario _0Local _993632
830		0	_aAdvances in Experimental Medicine and Biology _x0065-2598 _v846 _9133153
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-12114-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319121147
907			_a.b1289882x _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b10-03-17 _cm _dz _eo _feng _ggw _h0
945			_aQP572.P74 R434 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11568446 _z06-04-17
999			_c81292 _d81292 _x1